Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders
Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders
复制标题
DOI：
10.1111/j.1749-6632.2012.06667.x
复制
发表时间：
2012-01-01
期刊：
影响因子：
--
通讯作者：
Fibbe, Willem E.
中科院分区：
文献类型：
--
作者：
Bernardo, Maria Ester;Fibbe, Willem E.
间充质基质细胞（MSC）正在临床试验中用于促进移植和治疗造血干细胞移植后的类固醇抗性急性移植物抗宿主病，以及修复炎性/退行性疾病（特别是炎性肠病（IBD））中的组织损伤。当进入临床竞技场时，必须考虑MSC疗法的一些潜在风险：（i）细胞的免疫原性，（ii）培养基组分的生物安全性，（iii）异位组织形成的风险，和（iv）扩增期间细胞的潜在体外转化。本文分析了在细胞治疗方法中使用MSC的主要风险，并报告了在再生医学背景下使用MSC的一些最有趣的发现。综述了使用间充质干细胞治疗IBD和其他炎症/退行性疾病的动物模型实验研究和I/II期临床试验。
Mesenchymal stromal cells (MSCs) are being employed in clinical trials to facilitate engraftment and to treat steroid-resistant acute graft-versus-host disease after hematopoietic stem cell transplantation, as well as to repair tissue damage in inflammatory/degenerative disorders, in particular, in inflammatory bowel diseases (IBDs). When entering the clinical arena, a few potential risks of MSC therapy have to be taken into account: (i) immunogenicity of the cells, (ii) biosafety of medium components, (iii) risk of ectopic tissue formation, and (iv) potential in vitro transformation of the cells during expansion. This paper analyzes the main risks connected with the use of MSCs in cellular therapy approaches, and reports on some of the most intriguing findings on the use of MSCs in the context of regenerative medicine. Experimental studies in animal models and phase I/II clinical trials on the use of MSCs for the treatment of IBDs and other inflammatory/degenerative conditions are reviewed.